What’s the current market cap for Jazz Pharmaceuticals stock?

Jazz Pharmaceuticals (JAZZ) has a market cap of $15B as of May 22, 2026.

What is the P/E ratio for Jazz Pharmaceuticals stock?

The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 506.7 as of May 22, 2026.

Does Jazz Pharmaceuticals stock pay dividends?

No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of May 22, 2026.

When is the next Jazz Pharmaceuticals dividend payment date?

Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.

What is the beta indicator for Jazz Pharmaceuticals?

Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Jazz Pharmaceuticals stock | $JAZZ Share Price

13:30

15:10

16:45

18:25

20:00

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Ticker

$JAZZ

Sector

Health

Primary listing

NASDAQ

Employees

2,890

Headquarters

Dublin, Ireland

Website

www.jazzpharma.com

JAZZ Metrics

BasicAdvanced

$15bn

506.70

$0.47

0.27

What the Analysts think about JAZZ

Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.

Bulls say / Bears say

Q3 2025 revenue rose 7% year-over-year to $1.13 billion, surpassing the $1.11 billion consensus, and adjusted EPS was $8.13, above the $5.92 estimate, showing strong operational performance.

Core franchises posted double-digit sales growth in Q3, with Xywav and Epidiolex benefiting from greater patient adoption and favorable gross-to-net trends.

In Q1 2026, revenue climbed 19% YoY to $1.07 billion—beating the $981 million consensus—and Jazz reiterated its full-year 2026 guidance of $4.25–$4.50 billion, reflecting ongoing momentum.

Zepzelca sales fell in Q3 2025 despite its approval as a maintenance therapy for extensive-stage small cell lung cancer, pointing to inconsistent uptake within Jazz’s oncology segment.

Jazz posted a GAAP net loss of $356 million in 2025, reversing a $560 million profit in 2024, mainly due to $947.9 million in acquired in-process R&D expenses and sizable litigation settlements, which underscores risks to profitability.

As of December 31, 2025, Jazz had $2.44 billion in cash versus $5.36 billion in long-term debt, creating a significant net debt load that could limit financial flexibility if revenue growth slows.

Data summarised monthly by Lightyear AI. Last updated on 13 May 2026.

JAZZ Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

JAZZ Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JAZZ

Capital at risk

Market closed

Upcoming events

No upcoming events